BEAM Relative Valuation
BEAM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BEAM is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for BEAM's competitors is 957.20, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM) exhibits a P/S ratio of 26.65, which is -97.22% above the industry average. Given its robust revenue growth of 0.81%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Beam Therapeutics Inc (BEAM) currently overvalued or undervalued?
What is Beam Therapeutics Inc (BEAM) fair value?
How does BEAM's valuation metrics compare to the industry average?
What is the current P/B ratio for Beam Therapeutics Inc (BEAM) as of May 20 2025?
What is the current FCF Yield for Beam Therapeutics Inc (BEAM) as of May 20 2025?
What is the current Forward P/E ratio for Beam Therapeutics Inc (BEAM) as of May 20 2025?